Gwenn Hansen Sells 3,847 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 3,847 shares of the stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $23.38, for a total transaction of $89,942.86. Following the completion of the sale, the insider directly owned 121,338 shares in the company, valued at approximately $2,836,882.44. This trade represents a 3.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Gwenn Hansen also recently made the following trade(s):

• On Thursday, June 25th, Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $107,880.00.

Nurix Therapeutics Stock Down 1.6%

Nurix Therapeutics stock opened at $23.21 on Friday. Nurix Therapeutics, Inc. has a 52-week low of $8.19 and a 52-week high of $25.08. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of -6.73 and a beta of 1.80. The firm has a 50-day moving average price of $20.54 and a two-hundred day moving average price of $17.85.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The firm had revenue of $9.04 million during the quarter, compared to analyst estimates of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. Research analysts expect that Nurix Therapeutics, Inc. will post -2.84 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Larson Financial Group LLC increased its stake in shares of Nurix Therapeutics by 339.0% during the fourth quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock valued at $29,000 after acquiring an additional 1,190 shares during the period. California State Teachers Retirement System lifted its position in Nurix Therapeutics by 2.2% in the fourth quarter. California State Teachers Retirement System now owns 68,019 shares of the company’s stock worth $1,290,000 after purchasing an additional 1,476 shares during the period. Intesa Sanpaolo Wealth Management bought a new position in Nurix Therapeutics during the 4th quarter valued at $31,000. Royal Bank of Canada boosted its stake in Nurix Therapeutics by 17.6% during the 4th quarter. Royal Bank of Canada now owns 10,842 shares of the company’s stock valued at $206,000 after purchasing an additional 1,623 shares in the last quarter. Finally, Arizona State Retirement System boosted its stake in Nurix Therapeutics by 8.2% during the 4th quarter. Arizona State Retirement System now owns 21,990 shares of the company’s stock valued at $417,000 after purchasing an additional 1,674 shares in the last quarter.

Wall Street Analysts Forecast Growth

NRIX has been the topic of several analyst reports. Stifel Nicolaus raised their target price on Nurix Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Truist Financial boosted their price target on Nurix Therapeutics from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Wall Street Zen raised Nurix Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. Robert W. Baird raised their price target on Nurix Therapeutics from $26.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Finally, Mizuho raised their price target on Nurix Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.00.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.